Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Development of Diffusion MRI and Tractography Technique for the Detection of Nerve Lesions in Brachial Plexus Injuries

NCT07767708 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2026-01-09
Last updated
2026-08-17

Condition(s) studied

Obstetric Brachial Plexus Palsy

Investigational drug(s) / intervention(s)

Performing an MRI

Performing an MRI: Various MRI sequences were performed (without injection) according to a new protocol developed at the ICM. This acquisition protocol consists of anatomical and diffusion sequences lasting approximately 1 hour. The acquisitions were performed in a 3T MRI scanner, in the supine position with the palms facing upwards. Gadolinium was not used in our study.

Study summary

The objective of this prospective study is to contribute to improving the management of patients with obstetric brachial plexus palsy.

The main objective is the characterization of the microstructure by diffusion MRI in patients with a history of unoperated obstetrical brachial plexus palsy.

Eligibility

Sex
ALL
Min age
14 Years
Max age
30 Years
Healthy volunteers
No
Inclusion Criteria: * Patients aged 14 to 30 years * Consulted by the Orthopedics Department at Armand Trousseau Hospital * Diagnosed and monitored by Armand Trousseau Hospital for obstetrical brachial plexus palsy (OBBP) * Having a single, unoperated lesion (lesions are very different and only exceptionally affect all the roots bilaterally). * Not suffering from bone or neurological pathology unrelated to OBP * Patients affiliated with or entitled to a social security scheme * Patients who have received informed information and have signed, with the investigator, a consent form to participate in the study * Parents/legal guardians who have received informed information and have co-signed, with the investigator, a consent form to participate in the study, for minor patients Exclusion Criteria: * History of rheumatoid pathologies, constitutional bone diseases, past or current pathologies affecting the arm or neck unrelated to the obstetric brachial plexus, any history of neoplasia or radiographic appearance consistent with a neoplastic fracture * Current pregnancy * Inability to perform the MRI examination (presence of a contraindication, incapacitating pain, or claustrophobia) * Large tattoo present in the area of interest (artifacts) * Patients deprived of liberty, or under guardianship/curatorship * Patients receiving medical assistance (AME)

Primary outcome measure(s)

  • Characterization of the microstructure by MRI diffusion in patients with a history of unoperated obstetrical brachial plexus palsy (OBBP) — 3 months max.
    Extraction of diffusion tensor parameters (measurement of signal anisotropy ) along the different nerves constituting the brachial plexus, reconstructed using tractography.
  • Characterization of the microstructure by MRI diffusion in patients with a history of unoperated obstetrical brachial plexus palsy (OBBP) — 3 months max.
    Extraction of diffusion tensor parameters, measurement of diffusivity, along the different nerves constituting the brachial plexus, reconstructed using tractography
  • Characterization of the microstructure by MRI diffusion in patients with a history of unoperated obstetrical brachial plexus palsy (OBBP) — 3 months max.
    Comparison of metrics (Anitropy Fraction, Mean Diffusion) of healthy versus injured nerves. Each plexus is manually segmented by ITK SNAP in order to extract the nerve pathways of each plexus.
  • Characterization of the microstructure by MRI diffusion in patients with a history of unoperated obstetrical brachial plexus palsy (OBBP) — 3 months max.
    Description of FA, MD parameter measurements on tractography sequences along the complete pathway of the brachial plexus nerves

Trial sites (1)

FacilityCityRegionStatus
Service de Chirurgie Orthopédique et Réparatrice de l'Enfant, Hôpital Armand Trousseau AP-HP Paris France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07767708 on ClinicalTrials.gov ↗ ← All trials in France